NBP (NovaBridge Biosciences) Current Accrued Expense: $11.13 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBP NovaBridge Biosciences NBP
30 GF Score
Price $1.60
! 5 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Current Accrued Expense?

NovaBridge Biosciences NBP -5.92% 30 Current Accrued Expense is $11.13 Mil as of Jun. 2026. GuruFocus rates NBP with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

NovaBridge Biosciences's Current Accrued Expense for the quarter that ended in Jun. 2026 was $11.13 Mil.

NovaBridge Biosciences's quarterly Current Accrued Expense increased from Jun. 2025 ($6.49 Mil) to Dec. 2025 ($16.82 Mil) but then declined from Dec. 2025 ($16.82 Mil) to Jun. 2026 ($11.13 Mil).

NovaBridge Biosciences's annual Current Accrued Expense declined from Dec. 2023 ($7.85 Mil) to Dec. 2024 ($7.53 Mil) but then increased from Dec. 2024 ($7.53 Mil) to Dec. 2025 ($16.82 Mil).

NovaBridge Biosciences Current Accrued Expense Related Terms

NovaBridge Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences Current Accrued Expense Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 84.47 84.76 7.85 7.53 16.82

NovaBridge Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.26 7.53 6.49 16.82 11.13
NBP
30GF Score
NovaBridge Biosciences NBP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $11.13 Mil mean?
NovaBridge Biosciences (NBP) has a Current Accrued Expense of $11.13 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Current Accrued Expense too high?
NovaBridge Biosciences' current Current Accrued Expense is $11.13 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Current Accrued Expense compare to PEPG and DTIL?
NovaBridge Biosciences' Current Accrued Expense of $11.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Current Accrued Expense is $11.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (NBP) has a current Current Accrued Expense of $11.13 Mil. The current Current Accrued Expense is $11.13 Mil. NovaBridge Biosciences' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For NovaBridge Biosciences (NBP), the current Current Accrued Expense is $11.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges 0VY:Germany
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score

Get the complete analysis for NBP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price